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Abstract
Background: Musculoskeletal diseases are becoming increasingly important due to population aging. However,
studies on the economic burden of musculoskeletal disease in Korea are scarce. Therefore, we conducted a
population-based study to measure the economic burden of musculoskeletal disease in Korea using nationally
representative data.
Methods: This study used a variety of data sources such as national health insurance statistics, the Korea Health
Panel study and cause of death reports generated by the Korea National Statistical Office to estimate the economic
burden of musculoskeletal disease. The total cost of musculoskeletal disease was estimated as the sum of direct
medical care costs, direct non-medical care costs, and indirect costs. Direct medical care costs are composed of the
costs paid by the insurer and patients, over the counter drugs costs, and other costs such as medical equipment
costs. Direct non-medical costs are composed of transportation and caregiver costs. Indirect costs are the sum of
the costs associated with premature death and the costs due to productivity loss. Age, sex, and disease specific
costs were estimated.
Results: Among the musculoskeletal diseases, the highest costs are associated with other dorsopathies, followed
by disc disorder and arthrosis. The direct medical and direct non-medical costs of all musculoskeletal diseases were
$4.18 billion and $338 million in 2008, respectively. Among the indirect costs, those due to productivity loss were
$2.28 billion and costs due to premature death were $79 million. The proportions of the total costs incurred by
male and female patients were 33.8% and 66.2%, respectively, and the cost due to the female adult aged 20-64
years old was highest. The total economic cost of musculoskeletal disease was $6.89 billion, which represents 0.7%
of the Korean gross domestic product.
Conclusions: The economic burden of musculoskeletal disease in Korea is substantial. As the Korean population
continues to age, the economic burden of musculoskeletal disease will continue to increase. Policy measures
aimed at controlling the cost of musculoskeletal disease are therefore required.
Background
Musculoskeletal disease includes osteoarthritis, rheuma-
toid arthritis, osteoporosis, and low back pain. These
diseases are public health concerns and have a heavy
burden on society owing to their chronic characteristics
and the associated severe pain. In addition, they also
affect the psychological health of patient families and
caregivers [1]. The burden of osteoarthritis was 2.5% of
the total disability adjusted life years (DALYs) in high-
income countries in 2001, where osteoarthritis was
ranked as the tenth leading cause of DALYs [2]. A study
conducted in 2004 determined that osteoarthritis
accounts for 4.1% of the total years lost to disability
(YLD), which ranks fifth among all diseases [3]. The
importance of musculoskeletal disease is also evident
from the results of studies conducted in individual
nations. For example, in the USA, the self-recognized
prevalence of arthritis was 30% among patients 18 years
or older. In those 65 years or older group, the preva-
lence rate was even 55% [4]. Additionally, a burden of
disease study in Singapore revealed that musculoskeletal
disease accounted for 4.8% of total DALYs in 2004 and
was the sixth leading cause of disease and injury behind
neurological and sense disorders [5].
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musculoskeletal disease follows cancer, cardiovascular dis-
ease, digestive disease, respiratory disease, and neuropsy-
chiatric disease to be ranked seventh in total DALYs for
major disease groups in 2002. Additionally, among muscu-
loskeletal diseases, rheumatoid arthritis ranks 14
th in
DALYs for males, while rheumatoid arthritis ranks fifth
and osteoarthritis ranks eighth for females [6].
Musculoskeletal disease is also a significant economic
burden. The economic cost of musculoskeletal disease
in Canada accounted for 3.4% of the GDP in 1994, and
it is estimated that the cost of musculoskeletal disease
was 7.7% of the GDP in the USA, which reached $849
billion dollars in 2004 [7,8]. In Korea, musculoskeletal
disease accounted for 28.2% of National Health Insur-
ance Corporation (NHIC) inpatient and outpatient
claims, 10.9% of NHIC benefits, and 0.27% of the GDP
in 2008 [9,10]. The self-recognized prevalence of
osteoarthritis, disc disorders, osteoporosis, and rheuma-
toid arthritis were reported to be 13.0%, 6.2%, 4.1%, and
2.2%, respectively, and the self-recognized population
prevalence of musculoskeletal disease was 19,720 per
100,000 persons in adults in 2005. Additionally, 73.1%
of women 65 years and older will have one or more
types of musculoskeletal disease such as osteoarthritis,
disc disorders, osteoporosis, or rheumatoid arthritis in
their lifetime [11]. Another study estimated musculoske-
letal disease prevalence using a questionnaire survey and
reported the prevalence of osteoarthritis, rheumatoid
arthritis, herniated discs, osteoporosis, spondyloarthro-
pathy, and gouty arthritis to be 3.2%, 1.6%, 1.1%, 0.8%,
0.3%, and 0.1%, respectively. However, these results dif-
fer from those of previous studies [12,13].
The prevalence of most musculoskeletal diseases
increase with age and are affected by lifestyle and habits
such as physical activity and obesity [1]. Significant
increases in the incidence and prevalence of musculos-
keletal disease are expected as a result of global popula-
tion aging and changing lifestyles. As a result, the
United Nations and the World Health Organization
endorsed 2000-2010 as the “Bone and Joint Decade” [1].
Social changes in Korea such as population aging,
increasing rates of obesity will soon make musculoskele-
tal disease a central public concern [14,15]. Adequate
policies will be required to facilitate the prevention and
management of musculoskeletal disease. Studies of the
pathophysiology, epidemiology, and burden of musculos-
keletal disease will be needed to inform policy makers.
Measuring the economic costs associated with muscu-
loskeletal disease facilitates an understanding of where
the greatest economic costs occur during treatment and
care, and this knowledge will in turn guide the creation
of public health policy [16]. However, the use of data
from other countries is limited in that the prevalence of
musculoskeletal disease varies by country and race.
Therefore, data from Korea-specific studies would be
the most helpful for application to the Korean popula-
tion; however, such studies are limited [13], especially
studies which focus on the economic burden of muscu-
loskeletal disease.
In this study, the importance of musculoskeletal dis-
ease in terms of economic burden was determined using
a number of data sources such as NHIC statistics, the
Korea Health Panel study, and cause of death reports
generated by the Korea National Statistical Office
(NSO).
Methods
This study measures the economic burden of musculos-
keletal disease using the prevalence approach, which
estimates the economic cost of all cases in a given per-
iod [17]. The costs of disease are classified as direct,
indirect, and intangible [18]. Direct costs are those asso-
ciated with direct medical care and direct non-medical
care. Direct medical costs are defined as the costs due
to diagnosis, treatment, continuing care, rehabilitation
and terminal care. Direct non-medical costs are costs
incurred through the use of non-health care resources
such as transportation, legal and court costs, cost of
relocating, and informal care. In contrast, indirect costs
include the opportunity costs associated with hospitali-
zation and outpatient visits, as well as those due to pre-
mature death. Intangible costs include the psychological
suffering resulting from the disease.
In this study, economic burden was measured using
the methodology outlined in previous studies [19,20].
Direct medical costs were measured as the sum of pay-
ments made by insurer and patients, OTC drugs and
other costs, such as medical equipment. In the case of
direct non-medical costs, transportation and caregiver
costs were estimated. Productivity loss was calculated
for patients up to 65 years of age. Intangible costs were
excluded in this study due to their subjectivity [18].
This study limited musculoskeletal disease to “M00-
M99” as defined by the International Classification of
Diseases (ICD) 10 [21]. Therefore, injury due to trauma
was excluded. Musculoskeletal disease was further sub-
divided into 11 categories according to the Korean clas-
sification of 298 diseases [22]: inflammatory
polyarthropathies (M05-M14), arthrosis (M15-M19),
acquired deformities of the limb(s) (M20-M21), other
arthropathies (M00-M03, M22-M25), systemic connec-
tive tissue disorder (M30-M36), cervical or other inter-
vertebral disorder (M50-M51), other dorsopathies (M40-
M49, M53-M54), soft tissue disorder (M60-M79), disor-
der of bone density and structure disorders (M80-M85),
osteomyelitis (M86), and other disorders resulting from
musculoskeletal disease (M87-M99).
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and the NHIC is the exclusive insurer, NHIC claims
data are nationally representative of medical care costs
covered by the Korean insurance program [23,24]. How-
ever, NHIC claims data do not include non-covered
costs such as elective services, caregiver costs, and over
the counter (OTC) drugs costs. In order to supply this
missing information, data from the Korea Health Panel
were used in this study.
The Korea Health Panel study was conducted in 2007
through collaboration between the Korea Institute for
Health and Social Affairs and the NHIC to determine
the health service use behaviour of patients and medical
expenditures [25]. The survey sample was extracted
using two-stage cluster stratified sampling from the
2005 Korean census. A pilot test was conducted in
2 0 0 7 ,a n dt h ef i r s ts t u d yw a v ew a sc o n d u c t e di n2 0 0 8 .
The survey was composed of about 200 questionnaires
and interviews conducted by trained interviewers. The
survey was performed on household, individual, and
case bases. The household study included questions
about the general characteristics, living expenses, pur-
chase of pharmaceutical products, and private health
insurance and premiums of the household. The indivi-
dual study considered demographic characteristics of
the subjects. The case-based study included those with
chronic diseases, inpatients, outpatients, and emergency
service utilization. In the case of chronic disease, survey
subjects were asked whether they had a chronic disease.
If they responded positively, then they were asked
whether they had been diagnosed by physician.
In our study, the data sources were utilized as follows.
First, the first round of the Korea Health Panel data was
used to determine the prevalence of musculoskeletal dis-
ease. Musculoskeletal disease patients were defined as
those who responded that they had a chronic musculoske-
letal disease that had been diagnosed by a doctor. In the
Korea Health panel, diseases are coded according to the
Korean classification of 298 diseases. Patients diagnosed
with any of the 11 musculoskeletal diseases in this classifi-
cation were defined as musculoskeletal patients (inflam-
matory polyarthropathies (M05-M14), arthrosis (M15-
M19), acquired deformities of the limb(s) (M20-M21),
other arthropathies (M00-M03, M22-M25), systemic con-
nective tissue disorders (M30-M36), cervical or other
intervertebral disorders (M50-M51), other dorsopathies
(M40-M49, M53-M54), soft tissue disorders (M60-M79),
disorders of bone density and structure disorders (M80-
M85), osteomyelitis (M86), and other disorders associated
with musculoskeletal disease (M87-M99)). Some subjects
in the survey had multiple chronic diseases. Subjects were
diagnosed as musculoskeletal patients if they had at least
one musculoskeletal disease. The prevalence rate was mea-
sured as the proportion of musculoskeletal patients among
the participants of the Korea Health Panel according to
age group (0-19 years old, 20-64 years old and ≥65 years
old). The population of Korea was multiplied by the preva-
lence rate to estimate the numbers of patients with mus-
culoskeletal diseases.
Among the economic cost, medical care costs paid by
insurer were estimated using NHIC statistics for the
year 2008 [8]. Additionally, copayment costs and non-
covered care costs were estimated using the first round
of the 2008 Korea Health Panel data and were estimated
as patient costs. OTC drugs costs and other costs such
as medical equipment costs were also estimated using
the first round of the 2008 Korea Health Panel data. In
the breakdown of direct non-medical costs, transporta-
tion costs were estimated using the first round of the
2008 Korea Health Panel data, and caregiver costs were
estimated from NHIC statistics. Indirect costs were
composed of premature death costs and productivity
losses due to hospital admission and outpatient visits.
The total numbers of admission days were acquired
from NHIC statistics, and the number of outpatient vis-
its was estimated from the Korea Health Panel data.
Cause of death data as reported by the National Statisti-
cal Office (NSO) in 2008 were used to estimate the cost
of premature death. Likewise, the total population figure
used in this study was the NSO’s estimated population
for 2008 [15]. All measured costs were calculated in US
dollars (1$ = 1104.7 won) [26].
Inpatient, outpatient, and emergency service due to
musculoskeletal disease according Korea Health Panel
data were analysed to estimate the payment by patients.
Some patients had multiple reasons for using these ser-
v i c e s ,b u ti fa tl e a s to n eo ft h ep a t i e n td i a g n o s e sw a s
musculoskeletal disease, these visits were considered in
this study. The costs paid by patients were adjusted by
the number of chronic diseases reported. However, the
cost of each musculoskeletal disease was classified
according to the major diagnosis. The study period for
the first round of the Korea Health Panel was 192.1
days and was adjusted to annual cost. The total cost to
the Korean population was estimated as the total popu-
lation compared to the number of subjects surveyed in
the Korea Health Panel. Also, the cost of OTC drugs
and other costs were determined from the Korea Health
Panel data. Other costs included the cost of medical
equipment, herbal medicine expenditures, health supple-
ment food, and sanitary aid associated with musculoske-
letal disease. OTC drugs and other costs were surveyed
by household in the Korea Health Panel. Musculoskele-
tal disease patients were identified, and household OTC
costs and other costs were analysed from this data.
Finally, costs were adjusted according to the number of
persons in each household and the number of chronic
diseases in the musculoskeletal patients.
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ent costs + emergency service costs)*(365/192.1)*(the
population of Korea in 2008/the number of subjects
surveyed).
OTC drugs costs = (OTC drugs costs for musculoske-
letal disease) * (365/192.1) * (the population of Korea in
2008/the number of subjects surveyed).
Other costs = (medical equipment costs + herbal med-
icine expenditure in market or pharmacy cost + health
supplement food costs + sanitary aid costs)*(365/192.1)*
(the population of Korea in 2008/the number of subjects
surveyed).
In the analysis of direct costs, transportation costs
were estimated using data from the Korea Health Panel
study. The frequencies of inpatient and outpatient ser-
vice use due to musculoskeletal disease were deter-
mined, and the average cost of transportation for
musculoskeletal disease patients was estimated. The
average cost of using medical services was estimated at
$0.58 per one way trip for outpatient service and $8.68
per one way trip for inpatient service.
Transportation Costs = inpatient transportation costs
+ outpatient transportation costs = (frequency of inpati-
ents with musculoskeletal disease * average one-way trip
cost of inpatients*2+ frequency of outpatients with mus-
culoskeletal disease *average one-way trip cost of outpa-
tients*2) *(365/192.1) *(the population of Korea in 2008/
the number of subjects surveyed).
In the case of caregiver costs, the cost and percentage
of patients who used a caregiver, including an informal
caregiver such as a relative or friend, were estimated
from data from the Korea Health Panel study, and the
admission day was estimated using NHIC statistics. The
average cost per day of paid caregivers for patients with
musculoskeletal disease was $45, and the percentage of
patients that used a caregiver was 74%.
Caregiver costs = (days of hospitalization*average care-
giver cost per day in 2008($45))* (the percentage of
caregiver utilization in musculoskeletal patients).
Indirect costs were divided into productivity loss costs
and premature death costs. Costs due to loss of
productivity were calculated from productivity loss due
to outpatient and inpatient visits for patients between
20 and 64 years of age. Average wage per day according
to age group was estimated from Ministry of Labor sta-
tistics [27]. For inpatients, the total duration of hospita-
lization was estimated from NHIC statistics, and for
outpatients, the number of outpatient visits per age
group was estimated using data from the Korea Health
Panel study. We regarded the productivity loss due to
outpatient visits as 1/3 that of the productivity loss for
inpatients per day [19].
Productivity loss = productivity loss of inpatients and
outpatients = days of hospitalization * average wage per
day + frequency of outpatient visits * average wage per
day*(1/3).
In order to estimate the cost of premature death, mor-
tality due to musculoskeletal disease was determined for
each age and sex group using cause of death reports
generated by the National Statistical Office (NSO) [28].
Lost future wages of the deceased were acquired from
Ministry of Labor statistics a n dd i s c o u n t e db yf i v ep e r -
cent per year to obtain the present value of forgone
income [20]. Future income loss was calculated through
65 years of age. Finally, mortality due to musculoskeletal
disease was multiplied by the present value of future
income.
Premature death costs = present value of future
income according to age & sex * frequency of mortality
according to age &sex group.
This study used public data from the NHIC, the Korea
Health Panel and the NSO which do not have personal
identifiers, and data publishing was approved by each
organization’s ethics committee. This survey conformed
to the Declaration of Helsinki as well as to local legisla-
tion. The data were collected and analysed using Micro-
soft Excel and SAS 9.2 (SAS Institute, Inc., Cary, NC).
Results
Table 1 shows the estimated prevalence of musculoske-
letal disease determined using the Korea Health Panel.
The prevalence of musculoskeletal disease in male
Table 1 Prevalence per 100,000 persons and numbers of musculoskeletal diseases patients by age group in male and
female in Korea, 2008
Male Female
Population
* Prevalence
† Patients
* Population
* Prevalence
† Patients
*
0-19 years old 6167.7 334.1 20.6 5567.1 455.0 25.3
20-64 years old 16216.1 5697.3 923.9 15640.0 12605.3 19714.6
≥65 years old 2032.2 25092.3 509.9 2983.8 56657.2 16905.6
Total 24415.9 6412.8 1454.4 24190.9 15818.8 36873.5
*Unit: thousand persons
†Unit: per 100,000 persons.
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per 100,000 persons, and the prevalence for females of
the same age was 455.0 persons per 100,000 persons.
Prevalence increased with age. The prevalence in
females was 12,605.3 persons per 100,000, and 5,697.3
persons per 100,000 in males for those 20-64 years of
age. In those 65 years or older, the prevalence of muscu-
loskeletal disease was 25092.3 persons in males and
56,657.2 persons per 100,000 in females. The total num-
ber of patients with musculoskeletal disease was 5.4 mil-
lion, and the prevalence of musculoskeletal disease was
estimated to be 11,212.7 per 100,000 persons (Table 1).
The five most costly musculoskeletal diseases are
noted in Table 2. The most costly musculoskeletal dis-
ease was other dorsopathies (M40-49& M53-M54), cost-
ing a total of 1.42 billion dollars (536.2 million dollars
for males and 855.3 million dollars for females). The
next most costly musculoskeletal diseases were disc dis-
orders (1.32 billion dollars), arthrosis (1.24 billion dol-
lars), soft tissue disorders (1.11 billion dollars) and
inflammatory polyarthropathies (345 million dollars). In
the case of arthrosis, female patients accounted for 75%
of the total cost of this disorder (9.33 million dollars),
which is a much higher proportion than that for other
musculoskeletal diseases.
Direct medical care costs, direct non-medical care
costs, and indirect costs are shown in Table 3. Direct
medical care costs accounted for the highest proportion
of costs. Among direct medical care costs, costs paid by
insurer were the highest at 2.47 billion dollars, and costs
paid by patients, comprised of co-payments and non-
covered care costs, followed at 1.68 billion dollars.
Other costs, including medical equipment and health
supplement food, totalled 25 million dollars, and OTC
drugs costs were 11 million dollars. The total cost of
direct medical care was 4.18 billion dollars. Additionally,
the costs associated with caregivers and transportation
were 269 million dollars and 69 million dollars, respec-
tively. In total, direct costs were estimated as 4.52 billion
dollars.
Indirect costs were composed of productivity loss
costs and costs due to premature death. The cost due to
productivity loss was estimated to be 2.28 billion dollars.
The total number of deaths due to musculoskeletal dis-
ease was 1,699 according to NSO statistics (male: 513,
female: 1,156). The leading cause of death was disorders
of bone density and structures including osteoporosis,
which affected 676 patients. Mortality rates were higher
in females 65 years and older (565 people). The cost
due to premature death was 79 million dollars, and sys-
temic connective tissue disorders accounted for the
highest proportion of these costs (40 million dollars).
When costs were compared according to age group
and sex, costs for female adults aged 20-64 were the
highest (3.21 billion). However, when compared with
the population, the burden of musculoskeletal disease
was highest for aged females ($430 per person), fol-
lowed by aged males ($291), female adults ($205), and
male adults ($103). The proportions of costs for male
and female patients were 33.8% and 66.2%, respectively,
and those of direct medical care costs, direct non-medi-
cal care costs, and indirect costs were 60.8%, 4.9%, and
34.3%, respectively. Total costs, which included direct
costs and indirect costs, were 6.89 billion dollars
(Table 3).
Discussion
In this study, the prevalence of musculoskeletal disease
was estimated to be 11,212.7 persons per 100,000 and
the three most costly musculoskeletal diseases were
other dorsopathies, disc disorders, and arthrosis. Direct
medical costs accounted for more than half of the total
costs, and costs paid by insurer were 59% of the direct
medical costs. The costs paid by female adults aged 20-
64 were highest, but the economic burden per person
was heaviest for aged females (65 years and older
group). Males accounted for only one-third of the total
costs.
The prevalence of musculoskeletal disease in this
study is relatively low compared to those in previous
studies in Korea [11,12]. One study in Korea estimated
the population prevalence of musculoskeletal disease in
adults to be 19,720 per 100,000 according to annual
self-reported prevalence rate, and 16,340 per 100,000
Table 2 Economic burden and prevalence of the five most costly musculoskeletal disease, 2008
male female total
prevalence
* cost
† prevalence
* cost
† prevalence
* cost
†
Other dorsopathies 1808.5 563.2 3367.6 855.3 2604.1 1418.5
Disc disorders 1443.5 535.8 2213.2 781.9 1836.3 1317.7
Arthrosis 1609.4 307.5 7754.2 932.9 4745.1 1240.4
Soft tissue disorders 1161.4 381.1 2404.3 731.8 1795.7 1112.9
Inflammatory polyarthropathy 613.9 113.8 883.7 231.0 751.6 344.8
*Unit: per 100,000 persons
†Unit: million dollars.
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rates. Furthermore, the prevalence of musculoskeletal
disease in females 65 years or older was estimated at
73,100 per 100,000 [11]. The differences in these results
can be attributed to differences in the age groups stu-
died. In this study, the prevalence rate was calculated
out of the total population. The physician-diagnosed
prevalence rate for adults would then be 14989.6 per
100,000, a result similar to that found in previous stu-
dies [11].
Differences in case definition and the methodology
used to estimate prevalence could also result in differ-
ences in the estimation of disease prevalence. Hur et al.
[11] defined musculoskeletal disease as being comprised
of the main musculoskeletal diseases of osteoarthritis,
rheumatoid arthritis, osteoporosis and herniated discs.
Self-reported case defined by the patients of who have
disease more than three months during last year or cur-
rently suffering. Patients who have self-reported muscu-
loskeletal disease and diagnosed by physician were
considered physician diagnosed patients. In this study,
we considered all musculoskeletal diseases, and cases
were defined as those patients with a musculoskeletal
chronic disease which had been diagnosed by a physi-
cian. Additionally, the prevalence rate in this study was
estimated from the proportion, while the previous study
used weighting factors to estimate the prevalence [11].
Musculoskeletal disease prevalence varies in other stu-
dies. For example, one study in the United Kingdom
reported that 14.5% of adults had symptoms of muscu-
loskeletal disease in 2003 [29]. Another study estimated
the prevalence of musculoskeletal disease to range from
6.6% to 20.7% [30]. Moreover, prevalence rates vary
according to the type of musculoskeletal disease. For
example, the global prevalence of arthritis has been
reported to range from 0.5% to 36%. This large range
results from differing case definitions and investigation
methods, as well as differences in race and country [11].
Furthermore, variation in estimates of the economic
burden of musculoskeletal disease is due to differences
in the types of diseases included as well as the cost cal-
culation methods used. For example, in Canada, direct
and indirect costs associated with musculoskeletal dis-
ease were estimated to be 5.6 billion dollars and 13.5
billion dollars, respectively. Total economic costs in
1994 were estimated to be 19.2 billion, about 3.4% of
Table 3 Direct and indirect costs of musculoskeletal disease in Korea, 2008
Direct costs Indirect costs Total
costs
†
Age
group
Population Direct medical care costs Direct non-medical care
costs
Total
direct
costs
(thousand
persons)
Paid by
insurer
Paid by
patient
OTC
drugs
costs
Other
costs
Total direct
medical
care costs
*
Transportation Caregiver
costs
Lost
productivity
Cost of
premature
death
Male
0-19
years
6,168 17,954 39,549 47 97 57,647 506 2,901 61,054 0 640 61,694
20-64
years
16,216 443,446 361,346 2,092 4,760 811,644 11,144 66,877 889,666 753,139 31,248 1,674,052
≥65
years
2,032 368,355 169,309 2,099 1,879 541,643 7,518 43,610 592,771 0 0 592,771
Male
Cost
24,416 829,756 570,204 4,239 6,736 1,410,934 19,169 113,388 1,543,491 753,139 31,888 2,328,517
Female
0-19
years
5,567 35,514 22,019 43 83 57,658 474 3,992 62,125 0 2,505 64,630
20-64
years
15,640 877,142 625,749 4,761 11,667 1,519,320 22,484 92,053 1,633,856 1,530,437 45,028 3,209,321
≥65
years
2,984 728,612 459,014 2,377 6,494 1,196,497 26,857 60,027 1,283,382 0 0 1,283,382
Female
Cost
24,191 1,641,268 1,106,783 7,181 18,244 2,773,475 49,815 156,073 2,979,363 1,530,437 47,533 4,557,333
Total
Cost
48,607 2,471,024 1,676,987 11,419 24,980 4,184,409 68,984 269,461 4,522,854 2,283,575 79,421 6,885,850
OTC drugs: Over the counter drugs, Unit: thousand dollars
*Sum of costs paid by insurer + costs paid by patients + OTC drugs costs+ other costs
†Sum of direct costs + indirect costs.
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Canadian study, musculoskeletal disorders included inju-
ries, fractures, and neoplasms of musculoskeletal origin.
Direct costs also included the cost of nursing home
admissions. However, transportation costs were
excluded. In addition, future income was discounted at
6% annually. In Sweden, the economic cost of musculos-
keletal disease, including rheumatoid arthritis, osteoar-
thritis, back diagnoses and other musculoskeletal system
diseases, was 52,762 million Swedish Kronor in 1994
[31]. This represented about 3.14% of the Swedish GDP
in 1994 [32]. In the Swedish study, costs included inpa-
tient care, outpatient care and loss of productivity. In
the USA, the direct cost of musculoskeletal disease was
estimated at $510 billion and the indirect cost was $339
billion which were 7.7% of the GDP [8]. In USA study,
musculoskeletal injuries were included in the musculos-
keletal disease entity, and the cost of musculoskeletal
disease was measured by the individual patient. Total
costs were estimated as the sum of individual persons’
costs rather than the sum of cost components. Direct
costs due to disease and indirect costs due to earning
loss were measured, while costs due to premature mor-
tality were not considered. The total medical expendi-
tures of patients with musculoskeletal conditions were
$5,824. Additionally, incremental expenditures of mus-
culoskeletal patients were $1,789 compared to those
subjects with similar characteristics but without a diag-
nosis of musculoskeletal disease. The average earning
loss of musculoskeletal patients was $4,616 and the dif-
ference was $1,506 with those who did not have muscu-
loskeletal diseases. Total direct and indirect costs were
4.6% and 3.1% of the GDP, respectively, and incremental
direct and indirect costs were 1.4% and 1.0% [7]. There-
fore, the estimated economic burden of musculoskeletal
disease differs according to study design and methods.
In this study, direct costs were 65.7% of total costs
and the total cost of musculoskeletal disease was about
0.7% of the Korean GDP [10]. These results vary from
previous studies due to differences in study design and
country of study. For instance, costs due to musculoske-
letal injuries, neoplasms of musculoskeletal origin and
congenital malformations of the musculoskeletal system
such as spina bifida were not measured in this study.
Additionally, this relatively low proportion may be
related to the low levels of health care expenditures in
Korea [33].
When compared with other Korean studies using a
similar study design, the total cost of musculoskeletal
disease in 2002 ($6.89 billion) was lower than that of
cancer ($9.4 billion) [20]. The costs of disc disorders
and arthrosis were 4.83 times and 4.54 times higher
than that of allergic rhinitis, respectively [19].
In comparison, the economic burden of cancer in Korea
was 1.72% of the GDP in 2002.
Though the prevalence and economic burden of mus-
culoskeletal disease vary, the fact that the prevalence of
musculoskeletal disease wasf o u n dt ob eh i g h e ri nt h e
aged and in females in our study sample is consistent
with the results of most other studies [11,12,29,34].
Korea has a rapidly aging population due to a decrease
in birth rate and an increase in life expectancy. The per-
centage of the population 65 years or older will increase
from 10.3% in 2008 to 15.6% in 2020 and to 38.2% in
2050 [10]. The prevalence and economic burden of
musculoskeletal disease will increase in the coming
years. The cost of musculoskeletal disease is predicted
to increase by 8 billion dollars in 2020 and by 9.2 billion
dollars in 2050 [10], without taking into account addi-
tional cost increases resulting from income growth or
technological advances. Thus, musculoskeletal disease
will impose a heavier economic burden on Korea in the
near future.
In this study, other dorsopathies (M40-M49, M53-
M54) is the most costly disease entity. This includes the
low back pain category (M45-M48, M54 except M54.2)
of the Global Burden of Disease Study and also includes
deforming dorsopathies and dorsalgia [3]. Among dorso-
pathies, only disc disorders (M50-M51) are excluded
from the category of other dorsopathies. The fact that
this is a broad disease category could be behind these
high costs.
In this study, the classification of disease was based on
Korean standards. For example, though the definition of
arthrosis was consistent with that used in the Global
Burden of Disease Study [3], apart from other dorsopa-
thies, inflammatory polyarthropathies include various
disease categories such as rheumatoid arthritis, gout,
and others. This inconsistency could be a limitation for
an international comparison of individual diseases.
Several additional limitations should be noted in this
study. First, the Korea Health Panel which was used to
estimate components of cost and prevalence does not
include weighting factors to estimate national statistics,
therefore the accuracy of the cost components using
Korean Health Panel could be limited. Second, this
study did not consider the cost of disability due to dis-
ease or other intangible costs. Some musculoskeletal dis-
eases such as osteoarthritis could result in disability or
sequelae, so could result in reduced quality of life.
Hence, if these costs were considered, the economic
burden of musculoskeletal disease would be greater [35].
Additionally, we presumed that costs due to premature
death and productivity loss were not incurred by the
aged (those 65 years or older). However, these results
may have varied with a different assumption [20].
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Page 7 of 9Moreover, when using the NHIC statistics to estimate
costs according to sex, the proportion of costs according
to the Korea Health Panel study was used. Another lim-
itation is that the costs paid by patients did not distin-
guish between copayment costs and non-covered care
costs. Therefore, it is difficult to determine actual non-
covered care costs of musculoskeletal disease, which are
a public concern in Korea.
Conclusions
In conclusion, this study estimated the economic burden
of musculoskeletal disease including non-covered care
costs, OTC drugs costs, and other costs such as medical
equipment expenditures, which were not sufficiently
considered in previous studies. Furthermore, this study
is the first to estimate the economic burden of all mus-
culoskeletal diseases in Korea. In this study, the esti-
mated population prevalence of musculoskeletal disease
was 11212.7 persons per 100,000, and the economic
burden was 2.33 billion in males and 4.56 billion in
females, totalling 6.89 billion dollars and 0.7% of the
Korean GDP. The average economic burden of muscu-
loskeletal disease per person was highest in aged
females. As the Korean population ages, the economic
burden of musculoskeletal disease will continue to
increase. Therefore, adequate policy measures that mini-
mize the cost of musculoskeletal disease will be required
in the near future.
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